http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113908152-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a07bc3cf4400a7099cc076f54f23ddf |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-08 |
| filingDate | 2021-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_603e05c8e2b4e919aa0bdeded5e7bafb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c85395ddb8077deb1871bdeaf5bea883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89653fc6f655ec731a75f18544438a4c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_283676c5c020cdb1a9b7d493f837a3fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bd5104bab3df98eb3e5e1dd354db119 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c05be7e16169303c39856d741adc8955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27a5fb64064020e79c6d18861b0b2cc9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c61763c525ffc995179e255db1ed36a2 |
| publicationDate | 2022-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113908152-A |
| titleOfInvention | Use of canagliflozin and its analogs in the preparation of medicines for preventing and treating male reproductive dysfunction |
| abstract | The invention belongs to the technical field of biomedicine. In particular, it relates to the use of canagliflozin and its analogs in the preparation of medicines for preventing and treating male reproductive dysfunction. The research results of the present invention show that all levels of spermatogenic cells reappear in the seminiferous tubules of db/db mice treated with canagliflozin, and the arrangement is relatively regular, and at the same time, a small amount of sperm can also be seen in the lumen, and Canagliflozin treatment can significantly improve abnormal sperm quality, sperm count and sperm motility in db/db mice. In the present invention, canagliflozin and its analogs are used for the prevention or treatment of male reproductive dysfunction for the first time, and a relatively ideal therapeutic effect is obtained, which is used for clinical application in the treatment of male sterility, especially male sterility caused by diabetes or hyperglycemia. , provides a new prevention and treatment option with extremely high application value and social benefits. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023109783-A1 |
| priorityDate | 2021-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 191.